Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
$1,318.00
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 377,280 incident cases and 1.0 million prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 423,900 incident cases and 1.1 million prevalent cases by 2030.
- Roche’s Esbriet and Boehringer Ingelheim’s Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I. Therapies in development for IPF focus on a wide variety of targets. The most common administration route of pipeline drugs in development is the oral route.
- High-impact upcoming events for drugs in the IPF space comprise topline Phase IIb trial results for GB0139 and LYT-100, topline Phase II trial results for cudetaxestat, and topline Phase III trial results for pamrevlumab.
- The overall likelihood of approval of a Phase I respiratory-other asset is 5.7%, and the average probability a drug advances from Phase III is 47.1%. Drugs, on average, take 11.8 years from Phase I to approval, compared to 10.0 years in the overall respiratory space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 72% of trials in Phase I–II, and 28% in Phase III–IV.
- The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 23 trials.
- Boehringer Ingelheim leads the industry sponsors with the highest overall number of clinical trials for IPF
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Pharmacologic treatment
10 Non-pharmacologic treatments
12 EPIDEMIOLOGY
17 MARKETED DRUGS
19 PIPELINE DRUGS
27 KEY UPCOMING EVENTS
28 KEY REGULATORY EVENTS
28 Sandoz Launches First US Pirfenidone At-Risk After Court Triumphs
28 CHMP Recommends Pan-EU Approval for Pirfenidone AE
29 PROBABILITY OF SUCCESS
30 LICENSING AND ASSET ACQUISITION DEALS
30 AbbVie Gains New Immunology Antibody Platform With DJS Buy
30 Bridge Options Antifibrotic Candidate From CellionBioMed
30 AbbVie Pulls Back Collaboration With Morphic Therapeutic
30 AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target
31 AgomAb Follows Recent Series B Raise With Buyout Of Origo
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
39 BIBLIOGRAPHY
40 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of IPF, 2021–30
16 Figure 2: Trends in prevalent cases of IPF, 2021–30
19 Figure 3: Overview of pipeline drugs for IPF in the US
19 Figure 4: Pipeline drugs for IPF, by company
20 Figure 5: Pipeline drugs for IPF, by drug type
20 Figure 6: Pipeline drugs for IPF, by classification
27 Figure 7: Key upcoming events in IPF
29 Figure 8: Probability of success in the respiratory-other pipeline
33 Figure 9: Clinical trials in IPF
33 Figure 10: Top 10 drugs for clinical trials in IPF
34 Figure 11: Top 10 companies for clinical trials in IPF
34 Figure 12: Trial locations in IPF
35 Figure 13: IPF trials status
36 Figure 14: IPF trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of IPF, 2021–30
15 Table 2: Prevalent cases of IPF, 2021–30
18 Table 3: Marketed drugs for IPF
21 Table 4: Pipeline drugs for IPF in the US
32 Table 5: Historical global sales, by drug ($m), 2017–21
32 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Glioblastoma (GBM) 
Sign up to the